Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.44 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALPI | P09923 | 1/20 | 0.34 |
| ▸ | CCR3 | P51677 | 5/20 | 0.33 |
| ▸ | EP300 | Q09472 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | CYP27A1 | Q02318 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1891515 | 0.79 | TP53 (0.41) | CYP26A1KMT2AMEN1ALPIALDH1A1 | |
| SCHEMBL1891513 | 0.79 | TP53 (0.41) | CYP26A1KMT2AMEN1ALPIALDH1A1 | |
| SCHEMBL3855365 | 0.77 | CYP26A1 (0.37) | CYP26A1CCR3 | |
| SCHEMBL28377055 | 0.76 | HSD11B1 (0.50) | HSD11B1IKBKBDYRK2EGFRCYP26A1 | |
| SCHEMBL28211015 | 0.76 | TNF (0.51) | KMT2AMEN1CCR3 | |
| SCHEMBL28377057 | 0.76 | HSD11B1 (0.50) | HSD11B1IKBKBDYRK2EGFRCYP26A1 | |
| SCHEMBL2261719 | 0.74 | CYP1A2 (0.41) | KMT2AMEN1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL2258288 | 0.74 | CYP1A2 (0.41) | KMT2AMEN1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL27510746 | 0.74 | TP53 (0.41) | CYP26A1KMT2AMEN1ALPIALDH1A1 | |
| SCHEMBL11480321 | 0.73 | CYP1A2 (0.40) | KMT2AMEN1ALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1659111-A2 | Piperidine derivatives useful as ccr5 antagonists | Schering Corporation (US) | 2006-05-24 | — | — | EP | disclosed |
| EP-1175402-B1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORP (US) | 2005-07-20 | — | — | EP | disclosed |
| US-6602885-B2 | Piperidine derivatives useful as CCR5 antagonists | SCHERING CORPORATION | 2003-08-05 | — | — | US | disclosed |
| US-20030004185-A1 | Piperidine derivatives useful as CCR5 antagonists | MERCK SHARP & DOHME CORP. | 2003-01-02 | — | — | US | disclosed |
| US-6387930-B1 | ANTIARTHRITIC AGENTS; ANTIALLERGENS; SKIN DISORDERS; INFLAMMATORY BOWEL DISORDERS | SCHERING CORPORATION | 2002-05-14 | — | — | US | disclosed |
| EP-1175402-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000066559-A1 | PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS | SCHERING CORPORATION (US) | 2000-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004185-A1 | Piperidine derivatives useful as CCR5 antagonists | CCR5, CCR1, CCR2 | HSD11B1 1172/4885IKBKB 1073/4885DYRK2 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.